APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 262 filers reported holding APELLIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $3,808,926 | -11.7% | 57,746 | -30.8% | 1.14% | -6.0% |
| Q4 2022 | $4,314,993 | -4.2% | 83,446 | +26.5% | 1.22% | +0.3% |
| Q3 2022 | $4,504,000 | +2.8% | 65,946 | -32.0% | 1.21% | +1.3% |
| Q2 2022 | $4,383,000 | -8.2% | 96,935 | +3.2% | 1.20% | -3.9% |
| Q1 2022 | $4,773,000 | +494.4% | 93,935 | +639.5% | 1.24% | +640.5% |
| Q2 2021 | $803,000 | -58.4% | 12,703 | -71.7% | 0.17% | -63.2% |
| Q1 2021 | $1,928,000 | -23.2% | 44,926 | +2.3% | 0.46% | -38.8% |
| Q4 2020 | $2,512,000 | +177.0% | 43,916 | +46.1% | 0.75% | +153.2% |
| Q3 2020 | $907,000 | -17.2% | 30,054 | -10.4% | 0.30% | -6.6% |
| Q2 2020 | $1,096,000 | -24.3% | 33,554 | -37.9% | 0.32% | -47.7% |
| Q1 2020 | $1,448,000 | +16.3% | 54,054 | +33.0% | 0.60% | +41.5% |
| Q4 2019 | $1,245,000 | -69.6% | 40,657 | -76.1% | 0.43% | -72.2% |
| Q3 2019 | $4,090,000 | – | 169,800 | – | 1.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 3,130,000 | $119,065,200 | 18.29% |
| EcoR1 Capital, LLC | 10,899,859 | $414,630,636 | 13.99% |
| Ally Bridge Group (NY) LLC | 181,805 | $6,915,862 | 8.12% |
| Avoro Capital Advisors LLC | 11,111,111 | $422,666,662 | 6.59% |
| ACUTA CAPITAL PARTNERS, LLC | 244,484 | $9,300,171 | 6.23% |
| Iron Triangle Partners LP | 880,000 | $33,475,200 | 4.89% |
| Cormorant Asset Management, LP | 2,000,000 | $76,080,000 | 4.44% |
| Octagon Capital Advisors LP | 675,000 | $25,677,000 | 3.94% |
| Logos Global Management LP | 750,000 | $28,530,000 | 3.81% |
| Boxer Capital, LLC | 1,726,000 | $65,657,040 | 3.50% |